BORIS expression in ovarian cancer precursor cells alters the CTCF cistrome and enhances invasiveness through GALNT14

Joanna C. Hillman, Elena M. Pugacheva, Carter J. Barger, Sirinapa Sribenja, Spencer Rosario, Mustafa Albahrani, Alexander M. Truskinovsky, Aimee Stablewski, Song Liu, Dmitri I. Loukinov, Gabriel E. Zentner, Victor V. Lobanenkov, Adam R. Karpf, Michael J. Higgins

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

High-grade serous carcinoma (HGSC) is the most aggressive and predominant form of epithelial ovarian cancer and the leading cause of gynecologic cancer-related death. We have previously shown that CTCFL (also known as BORIS, Brother of the Regulator of Imprinted Sites) is expressed in most ovarian cancers, and is associated with global and promoter- specific DNA hypomethylation, advanced tumor stage, and poor prognosis. To explore its role in HGSC, we expressed BORIS in human fallopian tube secretory epithelial cells (FTSEC), the presumptive cells of origin for HGSC. BORISexpressing cells exhibited increased motility and invasion, and BORIS expression was associated with alterations in several cancer-associated gene expression networks, including fatty acid metabolism, TNF signaling, cell migration, and ECM- receptor interactions. Importantly, GALNT14, a glycosyltransferase gene implicated in cancer cell migration and invasion, was highly induced by BORIS, and GALNT14 knockdown significantly abrogated BORIS-induced cell motility and invasion. In addition, in silico analyses provided evidence for BORIS and GALNT14 coexpression in several cancers. Finally, ChIP-seq demonstrated that expression of BORIS was associated with de novo and enhanced binding of CTCF at hundreds of loci, many of which correlated with activation of transcription at target genes, including GALNT14. Taken together, our data indicate that BORIS may promote cell motility and invasion in HGSC via upregulation of GALNT14, and suggests BORIS as a potential therapeutic target in this malignancy.

Original languageEnglish (US)
Pages (from-to)2051-2062
Number of pages12
JournalMolecular Cancer Research
Volume17
Issue number10
DOIs
StatePublished - Oct 1 2019

Fingerprint

Ovarian Neoplasms
Cell Movement
Carcinoma
Neoplasms
Glycosyltransferases
Fallopian Tubes
Gene Regulatory Networks
Neoplasm Genes
Computer Simulation
Transcriptional Activation
Genes
Up-Regulation
Fatty Acids
Epithelial Cells
Gene Expression
DNA
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Hillman, J. C., Pugacheva, E. M., Barger, C. J., Sribenja, S., Rosario, S., Albahrani, M., ... Higgins, M. J. (2019). BORIS expression in ovarian cancer precursor cells alters the CTCF cistrome and enhances invasiveness through GALNT14. Molecular Cancer Research, 17(10), 2051-2062. https://doi.org/10.1158/1541-7786.MCR-19-0310

BORIS expression in ovarian cancer precursor cells alters the CTCF cistrome and enhances invasiveness through GALNT14. / Hillman, Joanna C.; Pugacheva, Elena M.; Barger, Carter J.; Sribenja, Sirinapa; Rosario, Spencer; Albahrani, Mustafa; Truskinovsky, Alexander M.; Stablewski, Aimee; Liu, Song; Loukinov, Dmitri I.; Zentner, Gabriel E.; Lobanenkov, Victor V.; Karpf, Adam R.; Higgins, Michael J.

In: Molecular Cancer Research, Vol. 17, No. 10, 01.10.2019, p. 2051-2062.

Research output: Contribution to journalArticle

Hillman, JC, Pugacheva, EM, Barger, CJ, Sribenja, S, Rosario, S, Albahrani, M, Truskinovsky, AM, Stablewski, A, Liu, S, Loukinov, DI, Zentner, GE, Lobanenkov, VV, Karpf, AR & Higgins, MJ 2019, 'BORIS expression in ovarian cancer precursor cells alters the CTCF cistrome and enhances invasiveness through GALNT14', Molecular Cancer Research, vol. 17, no. 10, pp. 2051-2062. https://doi.org/10.1158/1541-7786.MCR-19-0310
Hillman, Joanna C. ; Pugacheva, Elena M. ; Barger, Carter J. ; Sribenja, Sirinapa ; Rosario, Spencer ; Albahrani, Mustafa ; Truskinovsky, Alexander M. ; Stablewski, Aimee ; Liu, Song ; Loukinov, Dmitri I. ; Zentner, Gabriel E. ; Lobanenkov, Victor V. ; Karpf, Adam R. ; Higgins, Michael J. / BORIS expression in ovarian cancer precursor cells alters the CTCF cistrome and enhances invasiveness through GALNT14. In: Molecular Cancer Research. 2019 ; Vol. 17, No. 10. pp. 2051-2062.
@article{2c7ed8eb35374c41995a8aa6803a4a99,
title = "BORIS expression in ovarian cancer precursor cells alters the CTCF cistrome and enhances invasiveness through GALNT14",
abstract = "High-grade serous carcinoma (HGSC) is the most aggressive and predominant form of epithelial ovarian cancer and the leading cause of gynecologic cancer-related death. We have previously shown that CTCFL (also known as BORIS, Brother of the Regulator of Imprinted Sites) is expressed in most ovarian cancers, and is associated with global and promoter- specific DNA hypomethylation, advanced tumor stage, and poor prognosis. To explore its role in HGSC, we expressed BORIS in human fallopian tube secretory epithelial cells (FTSEC), the presumptive cells of origin for HGSC. BORISexpressing cells exhibited increased motility and invasion, and BORIS expression was associated with alterations in several cancer-associated gene expression networks, including fatty acid metabolism, TNF signaling, cell migration, and ECM- receptor interactions. Importantly, GALNT14, a glycosyltransferase gene implicated in cancer cell migration and invasion, was highly induced by BORIS, and GALNT14 knockdown significantly abrogated BORIS-induced cell motility and invasion. In addition, in silico analyses provided evidence for BORIS and GALNT14 coexpression in several cancers. Finally, ChIP-seq demonstrated that expression of BORIS was associated with de novo and enhanced binding of CTCF at hundreds of loci, many of which correlated with activation of transcription at target genes, including GALNT14. Taken together, our data indicate that BORIS may promote cell motility and invasion in HGSC via upregulation of GALNT14, and suggests BORIS as a potential therapeutic target in this malignancy.",
author = "Hillman, {Joanna C.} and Pugacheva, {Elena M.} and Barger, {Carter J.} and Sirinapa Sribenja and Spencer Rosario and Mustafa Albahrani and Truskinovsky, {Alexander M.} and Aimee Stablewski and Song Liu and Loukinov, {Dmitri I.} and Zentner, {Gabriel E.} and Lobanenkov, {Victor V.} and Karpf, {Adam R.} and Higgins, {Michael J.}",
year = "2019",
month = "10",
day = "1",
doi = "10.1158/1541-7786.MCR-19-0310",
language = "English (US)",
volume = "17",
pages = "2051--2062",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - BORIS expression in ovarian cancer precursor cells alters the CTCF cistrome and enhances invasiveness through GALNT14

AU - Hillman, Joanna C.

AU - Pugacheva, Elena M.

AU - Barger, Carter J.

AU - Sribenja, Sirinapa

AU - Rosario, Spencer

AU - Albahrani, Mustafa

AU - Truskinovsky, Alexander M.

AU - Stablewski, Aimee

AU - Liu, Song

AU - Loukinov, Dmitri I.

AU - Zentner, Gabriel E.

AU - Lobanenkov, Victor V.

AU - Karpf, Adam R.

AU - Higgins, Michael J.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - High-grade serous carcinoma (HGSC) is the most aggressive and predominant form of epithelial ovarian cancer and the leading cause of gynecologic cancer-related death. We have previously shown that CTCFL (also known as BORIS, Brother of the Regulator of Imprinted Sites) is expressed in most ovarian cancers, and is associated with global and promoter- specific DNA hypomethylation, advanced tumor stage, and poor prognosis. To explore its role in HGSC, we expressed BORIS in human fallopian tube secretory epithelial cells (FTSEC), the presumptive cells of origin for HGSC. BORISexpressing cells exhibited increased motility and invasion, and BORIS expression was associated with alterations in several cancer-associated gene expression networks, including fatty acid metabolism, TNF signaling, cell migration, and ECM- receptor interactions. Importantly, GALNT14, a glycosyltransferase gene implicated in cancer cell migration and invasion, was highly induced by BORIS, and GALNT14 knockdown significantly abrogated BORIS-induced cell motility and invasion. In addition, in silico analyses provided evidence for BORIS and GALNT14 coexpression in several cancers. Finally, ChIP-seq demonstrated that expression of BORIS was associated with de novo and enhanced binding of CTCF at hundreds of loci, many of which correlated with activation of transcription at target genes, including GALNT14. Taken together, our data indicate that BORIS may promote cell motility and invasion in HGSC via upregulation of GALNT14, and suggests BORIS as a potential therapeutic target in this malignancy.

AB - High-grade serous carcinoma (HGSC) is the most aggressive and predominant form of epithelial ovarian cancer and the leading cause of gynecologic cancer-related death. We have previously shown that CTCFL (also known as BORIS, Brother of the Regulator of Imprinted Sites) is expressed in most ovarian cancers, and is associated with global and promoter- specific DNA hypomethylation, advanced tumor stage, and poor prognosis. To explore its role in HGSC, we expressed BORIS in human fallopian tube secretory epithelial cells (FTSEC), the presumptive cells of origin for HGSC. BORISexpressing cells exhibited increased motility and invasion, and BORIS expression was associated with alterations in several cancer-associated gene expression networks, including fatty acid metabolism, TNF signaling, cell migration, and ECM- receptor interactions. Importantly, GALNT14, a glycosyltransferase gene implicated in cancer cell migration and invasion, was highly induced by BORIS, and GALNT14 knockdown significantly abrogated BORIS-induced cell motility and invasion. In addition, in silico analyses provided evidence for BORIS and GALNT14 coexpression in several cancers. Finally, ChIP-seq demonstrated that expression of BORIS was associated with de novo and enhanced binding of CTCF at hundreds of loci, many of which correlated with activation of transcription at target genes, including GALNT14. Taken together, our data indicate that BORIS may promote cell motility and invasion in HGSC via upregulation of GALNT14, and suggests BORIS as a potential therapeutic target in this malignancy.

UR - http://www.scopus.com/inward/record.url?scp=85072848617&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072848617&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-19-0310

DO - 10.1158/1541-7786.MCR-19-0310

M3 - Article

C2 - 31292201

AN - SCOPUS:85072848617

VL - 17

SP - 2051

EP - 2062

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 10

ER -